Disability-adjusted life years (DALYs) due to the direct health impact of COVID-19 in India, 2020
=================================================================================================

* Balbir B Singh
* Brecht Devleesschauwer
* Mehar S Khatkar
* Mark Lowerison
* Baljit Singh
* Navneet K Dhand
* Herman W Barkema

## Abstract

COVID-19 has affected all countries. Its containment represents a unique challenge for India due to a large population (>1.38 billion) across a wide range of population densities. Assessment of the COVID-19 disease burden is required to put the disease impact into context and support future pandemic policy development. Here, we present the national-level burden of COVID-19 in India in 2020 that accounts for differences across urban and rural regions and across age groups. Disability-adjusted life years (DALY) due to COVID-19 were estimated in the Indian population in 2020, comprised of years of life lost (YLL) and years lived with disability (YLD). Scenario analyses were conducted to account for excess deaths not recorded in the official data and for reported COVID-19 deaths. The direct impact of COVID-19 in 2020 in India was responsible for 14,106,060 (95% uncertainty interval [UI] 14,030,129–14,213,231) DALYs, consisting of 99.2% (95% UI 98.47–99.64%) YLLs and 0.80% (95% UI 0.36–1.53) YLDs. DALYs were higher in urban (56%; 95% UI 56–57%) than rural areas (44%; 95% UI 43.4–43.6) and in males (64%) than females (36%). In absolute terms, the highest DALYs occurred in the 51–60-year-old age group (28%) but the highest DALYs per 100,000 persons were estimated for the 71-80 year old age group (5,481; 95% UI 5,464–5,500 years). There were 4,823,791 (95% UI 4,760,908–4,924,307) DALYs after considering reported COVID-19 deaths only. The DALY estimations have direct and immediate implications not only for public policy in India, but also internationally given that India represents one sixth of the world’s population.

Keywords
*   COVID-19
*   Disability-adjusted life years
*   India
*   Years lived with disability
*   Years of life lost

## 1.0 Introduction

The coronavirus disease 2019 (COVID-19) pandemic 1 originated in Wuhan, China in December 2019 2 and eventually worldwide. The disease is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus that infects humans 3. As of 30 July 2021, 196,553,009 cumulative cases and 4,200,412 cumulative deaths have been reported worldwide 4. The virus spreads via respiratory droplets, and aerosols shed from infected individuals 5,6 or directly through contaminated hands 7. Important symptoms include fever, respiratory tract symptoms such as cough, pneumonia, shortness of breath and can progress to serious illness and even death 8,9. In addition, long or post-acute COVID-19 syndrome with symptoms and abnormalities after 12 weeks following the onset of acute COVID-19 infections has also been recognised 10.

The first case of COVID-19 in India was reported on 30 January 2020. The government of India implemented staged lockdowns and intense contact mitigation to overcome this challenge; however, these interventions were only able to slow but did not halt the spread of COVID-19 in India 11. As of 30 July 2021, 31,572,344 cumulative cases and 423,217 cumulative deaths have been reported in India 4. The adjusted case fatality risk (aCFR) due to COVID-19 in India has been reported to be 1.4 and 3.0% using random- and fixed-effects models, respectively 12. At the end of the first wave (15 February 2021), the cumulative aCFR declined to 1.2% using random and 1.6% using fixed-effects models 12. The aCFR in India was associated with co-morbidities such as the incidence of diabetes, cardiovascular diseases, hypertension, and acute respiratory infections 12.

The health impact of COVID-19 is being investigated across the globe. A recent study reported 1,279,866 deaths due to COVID-19 in 81 countries with an average of 16 years of life lost (YLL) per death resulting in 20,507,518 YLL 13. In the Kerala state of India, 709.2 DALYs per 100,000 population have been estimated from the inception of the pandemic to 20 August 2020 14. However, despite being the second most populous country in the world, no comprehensive assessment of the disease burden of COVID-19 in India has been undertaken. In this study, we estimated DALYs due to the direct health impact of COVID-19 in India from 30 January 2020 (the first case reported) to 31 December 2020. Domain, gender, and age-specific DALY estimates are provided to understand health impacts of COVID-19 in India.

## 2.0 Methods

### 2.1 COVID-19 case and death data

The COVID-19 cumulative case and death data till 31 December 2020 were extracted using the Government of India Ministry of Health and Family Welfare (MoHFW) COVID-19 tracker on 18 January 2021, 8:00 AM 15. Age-, gender- and domain-specific distributions of COVID-19 cases as provided by the National Centre for Disease Control, Government of India (as of 18 January 2021) were used in the analysis 16. The National Centre for Disease Control data on the proportion of deaths in various age groups as of 2 September 2020 were recorded from the published literature 17. Gender-specific mortality risk (64% in males and 36% in females) reported by the MoHFW were also recorded as of 21 May 2020 18. Domain-specific COVID-19 death data (rural vs urban) were obtained from the news item published online ([https://www.downtoearth.org.in/news/health/more-than-half-of-india-s-april-covid-19-deaths-were-in-rural-districts-76782](https://www.downtoearth.org.in/news/health/more-than-half-of-india-s-april-covid-19-deaths-were-in-rural-districts-76782)) indicating 56% deaths in urban and 44% deaths in rural districts during March 2020-April 2021.

Several studies indicate 48.5% 19, 52.5% 20, and 57.8% 21 of SARS-CoV-2 infected individuals remained asymptomatic in the country. A systematic review and meta-analysis conducted using the studies conducted worldwide till 10 June 2020 indicated 31% (95% CI 26–37%) of infected people to be asymptomatic 22. Based on all these studies, we assumed that 31–57.8% of infected people to be asymptomatic in the country.

As of 17 July 2020, the MoHFW reported that there were 2.8% cases on oxygen beds, 1.9% cases in intensive care units (ICUs), and 0.35% cases on ventilators 23. As of September 4, 2020, the MoHFW reported updated estimates of 3.5% cases on oxygen beds, 2.0% cases in ICUs, and 0.50% cases on ventilators 23. Based on both estimates, we assumed 4.8-5.5% of severe (patients in ICU plus those needing oxygen support), and 0.35-0.5% of critical (patients on ventilators) cases in the country. The proportion of cases that were not asymptomatic, severe or critical were assumed to be mild/moderate cases.

No data were available for the proportion of cases having post-acute COVID-19 syndrome (PCS) from India. A UK COVID symptom study indicates that approximately 10% of COVID-19 patients suffer from PCS 24,25. Other studies report that 51% of the patients in Spain 26 and 32.5% of patients in the United states 27 suffer from PCS. Based on the above-mentioned findings, we assumed that 32.5% of the mild/moderate, severe or critical cases would suffer from PCS in India. Details of COVID-19 cases and death input data have been presented in Table S1.

### 2.2 COVID-19 severity data

COVID-19 outcomes model and value of health loss as described by Wyper, et al. 28 were used in the current estimations 29,30. For COVID-19 infections, disability weight(s) of 0.051 (0.032-0.074) for mild/moderate, 0.133 (0.088-0.190) for severe, 0.655 (0.579-0.727) for critical, and 0.219 (0.148-0.308) for post-acute consequences cases were used. Per definition, the disability weight for asymptomatic cases equaled zero.

A mean duration of 7.79 days (6.20 - 9.64 days) has been estimated using meta-analysis for lower respiratory infections (LRI) 31. A study from India reported the interval to resolution of COVID-19 symptoms to be a median of 7.0 days (2.0-9.5 days) 32. Similarly, another study reported a median moderate COVID-19 duration of 6.0 days (3-11 days) 33. Based on all these estimates, we used a median of 7 days (2-11 days) as the disease duration for mild/moderate COVID-19 in India.

A study from India reported 12 days duration of COVID-19 for hospitalized patients 34. Another study from Germany also reported an overall hospitalization of 12 (7–20) days for COVID-19 patients needing oxygen supplementation outside the ICU 35. For critical patients, duration in the ICU for 9 (7-11) days has been reported 36. A Belgian study reported the time between symptom onset and hospitalization to vary from 3-10.4 days 37. Therefore, we used 18 (10-30.4) days as the disease duration for severe and critical COVID-19 (symptom onset to hospitalization duration plus hospitalization duration) in India.

A recent review on PCS indicated the duration of PCS in various countries varied from 1 to 6 months post-symptom onset, with a 2-month duration commonly reported 10. Therefore, we used a median of 60 days (30 – 180 days) as the disease duration for PCS in India. Details of COVID-19 severity-related input data have been presented in Table S1.

### 2.3 Demographic data

The human population in India for 2020 was projected to be 1,380,004,390 38. However, age-, domain- and gender-specific proportions of the population were not available for the year 2020. Therefore, we used the age-, domain- and gender-specific proportion of the population from the 2011 human population census data 39 assuming it to be constant for 2011 and 2020 population data. Life expectancy was derived as per the standard life expectancy table of Global Burden of Disease Study 2019 40. Details of demographic data have been presented in Table S1.

### 2.4 COVID-19 deaths

Excess deaths due to COVID-19 in India for the year 2020 were estimated (Table S1) using COVID-19 mortality estimates from March 2020 to May 2021 generated by the Institute for Health Metrics and Evaluation, Washington 41. Using the IHME data, the confidence interval of the proportion of the reported COVID-19 deaths to the excess deaths was estimated 42. We assumed that there will be a similar proportion of excess deaths during the year 2020 as reported from March 2020 to May 2021. As age, domain, and gender-specific proportion of excess deaths were unavailable, we assumed that the proportion of excess deaths will be similar to those reported for COVID-19 deaths.

### 2.5 Calculation of disability-adjusted life years

DALYs were estimated as the sum of YLDs and YLLs. YLL was estimated by multiplying the number of deaths due to COVID-19 by the residual standard life expectancy at the age of death due to the disease. YLD was calculated as a product of the number of incident cases of COVID-19, disease duration and disability weight. Domain-, gender- and age-specific DALYs were estimated as per Devleesschauwer et al. 2014a and 2014b 43,44. We assumed that cases were sick before dying; therefore, both YLDs and YLLs were estimated for COVID-19 deaths.

Scenario analyses were conducted using a) excess COVID-19 deaths reported by IHME 41, and b) officially reported deaths 15 to estimate DALYs associated with COVID-19 in India. Uncertainty was propagated using 10,000 Monte Carlo simulations. Uniform probability distributions were applied for the proportion of patients having mild/moderate, severe, or critical symptoms. Triangular distribution(s) were applied to disability weights and COVID-19 disease duration associated with various COVID-19 outcomes. A triangular distribution was also applied to excess COVID-19 deaths during the calendar year 2020.

The resulting uncertainty distributions were summarized by their mean and a 95% uncertainty interval (UI) defined as the distribution’s 2.5th and 97.5th percentile.

All analyses were conducted using R version 3.6.3 (R Development Core Team, [http://www.r-project.org](http://www.r-project.org)).

## 3.0 Results

### 3.1 Disability-adjusted life years

The direct impact of COVID-19 was responsible for 14,106,060 DALYs consisting of 13,992,803 (99.2%; 95% UI 98.47–99.64%) YLLs and 113,257 (0.80%; 95% UI 0.36– 1.53%) YLDs in 2020 in India (Table 1). There were 7,970,337 DALYs in urban (56%) as compared to 6,135,722 in rural (44%) areas (Table 1). There were 9,028,492 DALYs in males (64.0%) as compared to 5,077,568 DALYs in females (36.0%) (Table 1). The highest DALYs were reported in persons 51-60 years (3,922,508; 28%, Table 2). Mortality contributed towards almost all (99.2%) DALYs due to the direct impact of COVID-19 in India. There were 31.67 YLLs per COVID-19 death in the country. PCS contributed towards 89.61% (95% UI 79.1–95.62%) of the YLDs.

View this table:
[Table 1:](http://medrxiv.org/content/early/2021/08/22/2021.08.20.21262326/T1)

Table 1: Estimated annual disability adjusted life years (DALYs) due to excess COVID-19 deaths in 2020 in India.

View this table:
[Table 2:](http://medrxiv.org/content/early/2021/08/22/2021.08.20.21262326/T2)

Table 2: Estimated annual disability-adjusted life years (DALYs) due to excess COVID-19 deaths in various age groups in 2020 in India.

### 3.2 Disability-adjusted life years per 100,000 people

There were 1,022 DALYs, 1,014 YLLs, and 8 median YLDs per 100,000 persons per year in the country (Table 1). The median DALYs per 100,000 persons per year were higher in urban as compared to rural (1,854 *vs* 646) and in males as compared to females (1,270 vs 758) in India. The highest DALYs per 100,000 persons per year were at 5,481 (95% UI 5,464–5,500) reported in persons belonging to the age group of 71-80 years in India (Table 2).

### 3.3 Scenario analyses

The DALYs, YLLs and YLDs were approximately 3 times lower after considering reported COVID-19 deaths only (Table S2). There were 4,823,791 DALYs, 4,710,106 YLLs and 113,685 YLDs due to reported COVID-19 deaths. There were 349 DALYs, 341 YLLs and 8 YLDs per 100,000 persons per year due to reported COVID-19 deaths in the country (Table S2). A proportional decrease in age-wise DALYs and YLLs after excluding excess COVID-19 deaths is also presented in Table S3.

## 4.0 Discussion

We estimated DALYs due to the direct impact of COVID–19 in 2020 in India. Furthermore, we also accounted for excess COVID-19 deaths (not officially reported) for accurate DALY estimates. As far as we are aware, DALY estimations for COVID-19 for the full 2020 year have not been reported from India. Therefore, the current study will provide valuable insights into health impacts of COVID-19 in 2020 in India.

We believe IHME excess COVID-19 deaths prediction to be accurate, as it was based on models using week-by-week measurements of excess death rate during the ongoing COVID-19 pandemic. Furthermore, 6 drivers of all-cause mortality, including: a) the excess COVID-19 death rate, b) excess mortality due to delayed or deferred health care, c) excess mortality due to mental health disorders, d) reductions in mortality due to decrease in injuries, e) decrease in mortality due to other viruses, and f) and decrease in mortality due to certain chronic conditions, were also taken into account to accurately predict excess COVID-19 deaths nationally and various regions globally 41.

There was a loss of 1,022 healthy years of life per 100,000 person-years and 14 million DALYs due to the direct impact of COVID-19 in 2020 in India. In 2019, there were overall 468 million DALYs in India 45 indicating that the DALYs due to COVID-19 could account for almost 3% of the total DALYs in India. In 2017, the top 15 causes of DALYs per 1,000 person-years in India ranges from ischaemic heart disease (35.0) to fever of unknown origin (9.0) 46. Therefore, if excess deaths due to COVID-19 were accounted, the direct impact of COVID-19 would be among the top 15 causes but not among the top 10 of DALYs in 2020 in India. These estimates of direct impact of COVID-19 are lower than ischaemic heart disease, nutritional deficiencies, chronic respiratory diseases, neuropsychiatric conditions, diarrhoea, vision and other sensory loss, respiratory infections, cancers, stroke, road traffic accidents, tuberculosis, liver and alcohol-related conditions, but higher than musculoskeletal disorders and fever of unknown origin.

There are considerable variations among countries in estimated DALYs. For example, there were 1,767–1,981 DALYs per 100,000 person-years due to COVID-19 during 2020 in Scotland 47, 4.9 (20 January to 24 April 2020) in Korea 48, and 368 in Germany in 2020 49. There were 1200 YLLs per 100,000 capita during the first year of the pandemic in USA 50. Based on the reported COVID-19 death data, the DALYs per 100,000 person-years were approximately similar to those reported for Germany. However, after accounting for excess COVID-19 deaths, the DALYs per 100,000 person-years were much closer to those reported from the USA.

Median DALYs were higher in urban areas (56%) compared to rural areas. Similarly, urban-rural differences in exposures and outcomes of COVID-19 have been reported in the USA 51. This is because a high number of cases and deaths were reported from urban as compared to rural areas. Perhaps contact patterns are different in urban areas and rural areas. For example, a social contact rate of 17.0 in rural 52, 28.3 in urban developed centres and 67.4 in urban slum areas 53 per person per day was recorded in various domains in India.

Median DALYs were higher in males (64.0%) as compared to females (36.0%). Similar trends have been observed globally. Out of 121,449 DALYs in Italy, 82,020 were in males and 39,429 in females 54. Higher YLLs have been reported in males in 30 high incidence countries 55. Gender-specific DALY differences are due to a difference in proportion in cases and deaths among males and females. Furthermore, women have fewer contacts than men outside the home 52. In addition, being a male has been identified as a risk factor for death and ICU admission due to COVID-19 56.

Mortality contributed (99.61%) towards almost all the DALYs due to the direct impact of COVID-19 in India, in line with other studies 49,54,57. There was a median of 31.67 YLLs per COVID-19 death in India. This is because highest median YLLs were estimated for the population in the 51-60 year (3,906,065) and 61-70 year (3,256,690) age-groups, respectively. A study from two Indian states also reported that cases and deaths are concentrated in younger cohorts in the country as compared to high-income countries 58. Our DALY estimations were derived using the standard life expectancy table of Global Burden of Disease Study 2019 40. In Germany, 9.6 YLL per death have been reported; however, a higher YLL per death of 25.2 have been reported for persons under 70 years of age 49. YLL per COVID-19 death ranged from 15.3 to 15.5 in Scotland 59. However, these estimates could not be compared due to different life expectancy tables used in the analysis.

There are uncertainties surrounding these estimates. Undercounting or underreporting of COVID-19 cases and deaths is a serious concern and is more relevant in low- and middle-income countries such as India 60. We used IHME excess COVID-19 deaths and officially reported data to drive our estimates. As exact data on the total number of deaths during 2020 remain unavailable (India’s Civil Registration System data), DALYs after accounting for the exact number of excess deaths could not be estimated. Grey literature indicates that there were 13,297 more deaths during March-September 2020 as compared to the same period in 2019 and 14,944 as compared in 2018 in Mumbai, India ([https://timesofindia.indiatimes.com/city/mumbai/13k-more-deaths-in-city-this-year-between-march-sept/articleshow/78920631.cms](https://timesofindia.indiatimes.com/city/mumbai/13k-more-deaths-in-city-this-year-between-march-sept/articleshow/78920631.cms)). Conversely, the Kerala state of India reported an 11.1% reduction in all-cause mortality during 2020 as compared to 2019 61 possibly due to high reduction in other cause mortality as compared to COVID-19 associated excess mortality. Globally, comparative analyses using COVID-19 attributable and excess death approaches indicate that YLL estimations using attributable deaths maybe 3 times lower than those accounting for excess deaths; however, these estimates maybe even 12 times lower in some countries 13. To overcome this issue, we used excess mortality due to COVID-19 from March 2020 to May 2021 as estimated by the IHME, Washington 41. In addition, no data were available on age- and domain-specific proportions of excess deaths. We assumed this proportion to be similar to reported deaths. Therefore, the availability of all-cause mortality data in future will further refine COVID-19 associated DALY estimations in India. Furthermore, no data were available on the proportion of post-acute covid manifestations and was derived from other studies. This might have resulted in over or under estimation in the presented DALY. Lastly, indirect impact of COVID-19 especially due to disruption of health services could not be estimated.

Overall, direct impact of COVID-19 could be among the top 15 causes of DALYs in India. However, the estimated impact of COVID-19 would be substantially higher if indirect impacts of COVID-19 were to be accounted. Health impacts of COVID-19 varies in substantially in urban and rural areas. The current study will help to understand health impacts of COVID-19 in India and in other regions and countries.

## Supporting information

Table S1 [[supplements/262326_file03.docx]](pending:yes)

## Data Availability

The analysed data are available along with the manuscript. Sources of the raw data used in the analysis have been cited.

## CONFLICT OF INTEREST

The authors declare no conflicts of interest.

## ETHICAL STATEMENT

Informed consent for collection of epidemiological data was not required, as these data were already coded and available in the public domain. No identifiable personal information was used in this study.

## AUTHOR CONTRIBUTORS

BBS conceived the study. NKD, MSK and BD contributed to the conceptual model development. BBS build the model and conducted the analyses. BBS prepared the first draft of the paper which was reviewed and edited by NKD, MSK, HWB, ML, BS and BD. HWB and NKD coordinated the project and preparation of the manuscript.

## DATA AVAILABILITY STATEMENT

The analysed data are available along with the manuscript. Sources of the raw data used in the analysis have been cited.

## ACKNOWLEDGEMENTS

The authors acknowledge India’s National and State Health departments for collecting daily COVID-19 epidemic data and releasing it in the public domain.

*   Received August 20, 2021.
*   Revision received August 20, 2021.
*   Accepted August 21, 2021.


*   © 2021, Posted by Cold Spring Harbor Laboratory

This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at [http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/)

## References

1.  WHO. Listings of WHO’s response to COVID-19. (2020). <[https://www.who.int/news/item/29-06-2020-covidtimeline](https://www.who.int/news/item/29-06-2020-covidtimeline)>.
    
    

2.  Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270–273, doi:10.1038/s41586-020-2012-7 (2020).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/s41586-020-2012-7&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=32015507&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F08%2F22%2F2021.08.20.21262326.atom) 

3.  Andersen, K. G., Rambaut, A., Lipkin, W. I., Holmes, E. C. & Garry, R. F. The proximal origin of SARS-CoV-2. Nature Medicine 26, 450–452, doi:10.1038/s41591-020-0820-9 (2020).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/s41591-020-0820-9&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=32284615&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F08%2F22%2F2021.08.20.21262326.atom) 

4.  WHO. WHO Coronavirus (COVID-19) dashboard, <[https://covid19.who.int/region/searo/country/in](https://covid19.who.int/region/searo/country/in)> (2021).
    
    

5.  Lai, C.-C., Shih, T.-P., Ko, W.-C., Tang, H.-J. & Hsueh, P.-R. J. I. j. o. a. a. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and corona virus disease-2019 (COVID-19): the epidemic and the challenges. International Journal of Antimicrobial Agents 55, 105924, doi:[https://doi.org/10.1016/j.ijantimicag.2020.105924](https://doi.org/10.1016/j.ijantimicag.2020.105924) (2020).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.ijantimicag.2020.105924&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F08%2F22%2F2021.08.20.21262326.atom) 

6.  Somsen, G. A., van Rijn, C., Kooij, S., Bem, R. A. & Bonn, D. Small droplet aerosols in poorly ventilated spaces and SARS-CoV-2 transmission. The Lancet Respiratory Medicine 8, 658–659, doi:10.1016/S2213-2600(20)30245-9 (2020).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S2213-2600(20)30245-9&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=32473123&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F08%2F22%2F2021.08.20.21262326.atom) 

7.  Johnson, G. et al. Modality of human expired aerosol size distributions. Journal of Aerosol Science 42, 839–851 (2011).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.jaerosci.2011.07.009&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=20923611&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F08%2F22%2F2021.08.20.21262326.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000296165100001&link_type=ISI) 

8.  Chen, N. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet 395, 507–513, doi:10.1016/S0140-6736(20)30211-7 (2020).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S0140-6736(20)30211-7&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=32007143&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F08%2F22%2F2021.08.20.21262326.atom) 

9.  Wang, D. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. The Journal of American Medical Association 323, 1061–1069, doi:10.1001/jama.2020.1585 (2020).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1001/jama.2020.1585&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=32031570&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F08%2F22%2F2021.08.20.21262326.atom) 

10. Nalbandian, A. et al. Post-acute COVID-19 syndrome. Nature Medicine 27, 601–615, doi:10.1038/s41591-021-01283-z (2021).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/s41591-021-01283-z&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=33753937&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F08%2F22%2F2021.08.20.21262326.atom) 

11. Singh, B. B. et al. Public health interventions slowed but did not halt the spread of COVID-19 in India. Transboundary and Emerging Diseases 68, 2171–2187, doi:[https://doi.org/10.1111/tbed.13868](https://doi.org/10.1111/tbed.13868) (2020).
    
    

12. Singh, B. B. et al. Meta-analysis and adjusted estimation of COVID-19 case fatality risk in India and its association with the underlying comorbidities. One Health, doi:10.1016/j.onehlt.2021.100283 (2021).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.onehlt.2021.100283&link_type=DOI) 

13. Pifarré i Arolas, H. et al. Years of life lost to COVID-19 in 81 countries. Scientific Reports 11, 3504, doi:10.1038/s41598-021-83040-3 (2021).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/s41598-021-83040-3&link_type=DOI) 

14. Denny, J., Narassima, M. S., Jaideep, C. M. & Guru Rajesh, J. Estimation of economic burden of COVID-19 using disability-adjusted life years (DALYs) and productivity losses in Kerala state, India. Research Square, doi:10.21203/rs.3.rs-118146/v2 (2021).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.21203/rs.3.rs-118146/v2&link_type=DOI) 

15. MIB. COVID 19 Tracker. Ministry of Information and Broadcasting, Government of India., <[https://twitter.com/covidnewsbymib/status/1344505201332350977?lang=en](https://twitter.com/covidnewsbymib/status/1344505201332350977?lang=en)> (2020).
    
    

16. NCDC. National Centre for Disease Control. COVID-19 Dashboard., <[https://ncdc.gov.in/dashboard.php](https://ncdc.gov.in/dashboard.php)> (2021).
    
    

17. Indrayan, A., Mishra, A. & Pathak, M. Preliminary Estimates of Years of Life Lost (YLL) Due to COVID-19 in India. medRxiv, 2020.2010.2024.20218693, doi:10.1101/2020.10.24.20218693 (2020).
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NzoibWVkcnhpdiI7czo1OiJyZXNpZCI7czoyMToiMjAyMC4xMC4yNC4yMDIxODY5M3YzIjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjEvMDgvMjIvMjAyMS4wOC4yMC4yMTI2MjMyNi5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 

18. PIB. Press Information Bureau, Government of India. Updates on COVID-19. Release ID: 1625744., <[https://pib.gov.in/PressReleasePage.aspx?PRID=1625744](https://pib.gov.in/PressReleasePage.aspx?PRID=1625744)> (2020).
    
    

19. Krishnasamy, N. et al. Clinical Outcomes among Asymptomatic or Mildly Symptomatic COVID-19 Patients in an Isolation Facility in Chennai, India. The American Journal of Tropical Medicine and Hygiene 104, 85–90, doi:10.4269/ajtmh.20-1096 (2021).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.4269/ajtmh.20-1096&link_type=DOI) 

20. Saurabh, S. et al. Tobacco, alcohol use and other risk factors for developing symptomatic COVID-19 vs asymptomatic SARS-CoV-2 infection: a case-control study from western Rajasthan, India. Transactions of the Royal Society of Tropical Medicine and Hygiene 115, 820–831, doi:10.1093/trstmh/traa172 (2021).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/trstmh/traa172&link_type=DOI) 

21. Soni, S. L. et al. Demographic & clinical profile of patients with COVID-19 at a tertiary care hospital in north India. Indian J Med Res 153, 115–125, doi:10.4103/ijmr.IJMR\_2311\_20 (2021).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access\_num=10.4103/ijmr.IJMR_2311_20&link_type=DOI) 

22. Buitrago-Garcia, D. et al. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis. PLOS Medicine 17, e1003346, doi:10.1371/journal.pmed.1003346 (2020).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1371/journal.pmed.1003346&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=32960881&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F08%2F22%2F2021.08.20.21262326.atom) 

23. PIB. Press Information Bureau, Government of India. Home/All Press Release. Others. PIB’S daily bulletin on COVID-19., <[https://pib.gov.in/PressReleasePage.aspx?PRID=1639305](https://pib.gov.in/PressReleasePage.aspx?PRID=1639305); [https://pib.gov.in/PressReleasePage.aspx?PRID=1651364](https://pib.gov.in/PressReleasePage.aspx?PRID=1651364)> (2020).
    
    

24. Greenhalgh, T., Knight, M., A’Court, C., Buxton, M. & Husain, L. Management of post-acute covid-19 in primary care. BMJ 370, m3026, doi:10.1136/bmj.m3026 (2020).
    
    [FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiRlVMTCI7czoxMToiam91cm5hbENvZGUiO3M6MzoiYm1qIjtzOjU6InJlc2lkIjtzOjE3OiIzNzAvYXVnMTFfNS9tMzAyNiI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDIxLzA4LzIyLzIwMjEuMDguMjAuMjEyNjIzMjYuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 

25. CSS. COVID symptom study. How long does COVID-19 last? Kings College London, 2020., <[https://covid19.joinzoe.com/post/covid-long-term?fbclid=IwAR1RxIcmmdL-EFjh\_aI-](https://covid19.joinzoe.com/post/covid-long-term?fbclid=IwAR1RxIcmmdL-EFjh_aI)>. (2020).
    
    

26. Moreno-Pérez, O. et al. Post-acute COVID-19 syndrome. Incidence and risk factors: A Mediterranean cohort study. J Infect 82, 378–383, doi:10.1016/j.jinf.2021.01.004 (2021).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.jinf.2021.01.004&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=33450302&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F08%2F22%2F2021.08.20.21262326.atom) 

27. Logue, J. K. et al. Sequelae in Adults at 6 Months After COVID-19 Infection. JAMA Network Open 4, e210830–e210830, doi:10.1001/jamanetworkopen.2021.0830 (2021).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1001/jamanetworkopen.2021.0830&link_type=DOI) 

28. Wyper, G. M. A. et al. Burden of Disease Methods: A Guide to Calculate COVID-19 Disability-Adjusted Life Years. Int J Public Health 66, 1–5, doi:10.3389/ijph.2021.619011 (2021).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.3389/ijph.2021.619011&link_type=DOI) 

29. Haagsma, J. A. et al. Assessing disability weights based on the responses of 30,660 people from four European countries. Population Health Metrics 13, 10, doi:10.1186/s12963-015-0042-4 (2015).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1186/s12963-015-0042-4&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F08%2F22%2F2021.08.20.21262326.atom) 

30. Salomon, J. A. et al. Disability weights for the Global Burden of Disease 2013 study. The Lancet Global Health 3, e712–e723, doi:10.1016/S2214-109X(15)00069-8 (2015).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S2214-109X(15)00069-8&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=26475018&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F08%2F22%2F2021.08.20.21262326.atom) 

31. James, S. L. et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet 392, 1789–1858, doi:10.1016/S0140-6736(18)32279-7 (2018).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S0140-6736(18)32279-7&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=30496104&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F08%2F22%2F2021.08.20.21262326.atom) 

32. Kirtana, J. et al. Mild COVID-19 infection-predicting symptomatic phase and outcome: A study from AIIMS, New Delhi. J Family Med Prim Care 9, 5360–5365, doi:10.4103/jfmpc.jfmpc\_1610\_20 (2020).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access\_num=10.4103/jfmpc.jfmpc_1610_20&link_type=DOI) 

33. Agarwal, A. et al. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial). BMJ 371, m3939, doi:10.1136/bmj.m3939 (2020).
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MzoiYm1qIjtzOjU6InJlc2lkIjtzOjE3OiIzNzEvb2N0MjJfOC9tMzkzOSI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDIxLzA4LzIyLzIwMjEuMDguMjAuMjEyNjIzMjYuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 

34. Pannu, A. et al. Severe Acute Respiratory Infection Surveillance during the Initial Phase of the COVID-19 Outbreak in North India: A Comparison of COVID-19 to Other SARI Causes. Indian Journal of Critical Care Medicine 25, 761–767., doi:10.5005/jp-journals-10071-23882 (2021).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.5005/jp-journals-10071-23882&link_type=DOI) 

35. Daher, A. et al. Clinical course of COVID-19 patients needing supplemental oxygen outside the intensive care unit. Scientific Reports 11, 2256, doi:10.1038/s41598-021-81444-9 (2021).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/s41598-021-81444-9&link_type=DOI) 

36. Shukla, U., Chavali, S., Mukta, P., Mapari, A. & Vyas, A. Initial Experience of Critically Ill Patients with COVID-19 in Western India: A Case Series. Indian J Crit Care Med 24, 509–513, doi:10.5005/jp-journals-10071-23477 (2020).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.5005/jp-journals-10071-23477&link_type=DOI) 

37. Faes, C. et al. Time between Symptom Onset, Hospitalisation and Recovery or Death: Statistical Analysis of Belgian COVID-19 Patients. Int J Environ Res Public Health 17, 7560, doi:10.3390/ijerph17207560 (2020).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.3390/ijerph17207560&link_type=DOI) 

38. WorldBank. Population, total – India., <[https://data.worldbank.org/indicator/SP.POP.TOTL?locations=IN](https://data.worldbank.org/indicator/SP.POP.TOTL?locations=IN)> (2020).
    
    

39. COI. Census of India 2011. Population enumeration data (Final population), <[http://censusindia.gov.in/2011census/population_enumeration.html](http://censusindia.gov.in/2011census/population_enumeration.html); [http://censusindia.gov.in/2011-prov-results/indiaatglance.html](http://censusindia.gov.in/2011-prov-results/indiaatglance.html)> (2011).
    
    

40. GBDCN. Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2019 (GBD 2019) Reference Life Table. Seattle, United States of America: Institute for Health Metrics and Evaluation (IHME)., <[https://doi.org/10.6069/1D4Y-YQ37](https://doi.org/10.6069/1D4Y-YQ37)> (2021).
    
    

41. IHME. Institute for Health Metrics and Evaluation. Estimation of total mortality due to COVID-19., <[http://www.healthdata.org/special-analysis/estimation-excess-mortality-due-covid-19-and-scalars-reported-covid-19-deaths](http://www.healthdata.org/special-analysis/estimation-excess-mortality-due-covid-19-and-scalars-reported-covid-19-deaths)> (2021).
    
    

42. CIFPC. Confidence Interval For Proportions Calculator. (2021). <[https://stats.libretexts.org/@go/page/8347](https://stats.libretexts.org/@go/page/8347)>.
    
    

43. Devleesschauwer, B. et al. Calculating disability-adjusted life years to quantify burden of disease. International Journal of Public Health 59, 565–569, doi:10.1007/s00038-014-0552-z (2014).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1007/s00038-014-0552-z&link_type=DOI) 

44. Devleesschauwer, B. et al. DALY calculation in practice: a stepwise approach. International Journal of Public Health 59, 571–574, doi:10.1007/s00038-014-0553-y (2014).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1007/s00038-014-0553-y&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=24748107&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F08%2F22%2F2021.08.20.21262326.atom) 

45. Vos, T. et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet 396, 1204–1222, doi:10.1016/S0140-6736(20)30925-9 (2020).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S0140-6736(20)30925-9&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F08%2F22%2F2021.08.20.21262326.atom) 

46. Menon, G. R. et al. National Burden Estimates of healthy life lost in India, 2017: an analysis using direct mortality data and indirect disability data. The Lancet Global Health 7, e1675–e1684, doi:10.1016/S2214-109X(19)30451-6 (2019).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S2214-109X(19)30451-6&link_type=DOI) 

47. Wyper, G. et al. Inequalities in population health loss by multiple deprivation: COVID-19 and pre-pandemic all-cause disability-adjusted life years (DALYs) in Scotland. SocArXiv js3h6, doi:DOI: 10.31219/osf.io/js3h6 (2021).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.31219/osf.io/js3h6&link_type=DOI) 

48. Jo, M. W. et al. The Burden of Disease due to COVID-19 in Korea Using Disability-Adjusted Life Years. J Korean Med Sci 35, e199–e199, doi:10.3346/jkms.2020.35.e199 (2020).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.3346/jkms.2020.35.e199&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F08%2F22%2F2021.08.20.21262326.atom) 

49. Rommel, A. et al. The COVID-19 Disease Burden in Germany in 2020. Dtsch Arztebl International 118, 145–151 (2021).
    
    

50. Quast, T., Andel, R., Gregory, S. & Storch, E. A. Years of life lost associated with COVID-19 deaths in the USA during the first year of the pandemic. Journal of Public Health, doi:10.1093/pubmed/fdab123 (2021).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/pubmed/fdab123&link_type=DOI) 

51. Huang, Q. et al. Urban-rural differences in COVID-19 exposures and outcomes in the South: A preliminary analysis of South Carolina. PLoS One 16, e0246548, doi:10.1371/journal.pone.0246548 (2021).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1371/journal.pone.0246548&link_type=DOI) 

52. Kumar, S. et al. Who interacts with whom? Social mixing insights from a rural population in India. PLoS One 13, e0209039, doi:10.1371/journal.pone.0209039 (2018).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1371/journal.pone.0209039&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=30576333&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F08%2F22%2F2021.08.20.21262326.atom) 

53. Chen, J. et al. Effect of modelling slum populations on influenza spread in Delhi. BMJ open 6, e011699–e011699, doi:10.1136/bmjopen-2016-011699 (2016).
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NzoiYm1qb3BlbiI7czo1OiJyZXNpZCI7czoxMToiNi85L2UwMTE2OTkiO3M6NDoiYXRvbSI7czo1MDoiL21lZHJ4aXYvZWFybHkvMjAyMS8wOC8yMi8yMDIxLjA4LjIwLjIxMjYyMzI2LmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==) 

54. Nurchis, M. C. et al. Impact of the Burden of COVID-19 in Italy: Results of Disability-Adjusted Life Years (DALYs) and Productivity Loss. Int J Environ Res Public Health 17, 4233, doi:10.3390/ijerph17124233 (2020).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.3390/ijerph17124233&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=32545827&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F08%2F22%2F2021.08.20.21262326.atom) 

55. Oh, I. H. et al. Years of Life Lost Attributable to COVID-19 in High-incidence Countries. J Korean Med Sci 35, e300–e300, doi:10.3346/jkms.2020.35.e300 (2020).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.3346/jkms.2020.35.e300&link_type=DOI) 

56. Peckham, H. et al. Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission. Nature Communications 11, 6317, doi:10.1038/s41467-020-19741-6 (2020).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/s41467-020-19741-6&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F08%2F22%2F2021.08.20.21262326.atom) 

57. Zhao, J. et al. Disease Burden Attributable to the First Wave of COVID-19 in China and the Effect of Timing on the Cost-Effectiveness of Movement Restriction Policies. Value in Health 24, 615–624, doi:10.1016/j.jval.2020.12.009 (2021).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.jval.2020.12.009&link_type=DOI) 

58. Laxminarayan, R. et al. Epidemiology and transmission dynamics of COVID-19 in two Indian states. Science 370, 691, doi:10.1126/science.abd7672 (2020).
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6Mzoic2NpIjtzOjU6InJlc2lkIjtzOjEyOiIzNzAvNjUxNy82OTEiO3M6NDoiYXRvbSI7czo1MDoiL21lZHJ4aXYvZWFybHkvMjAyMS8wOC8yMi8yMDIxLjA4LjIwLjIxMjYyMzI2LmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==) 

59. Wyper, G. et al. Measuring the direct population impact of COVID-19 in Scotland, 2020: estimating disability-adjusted life years (DALYs) during the first full calendar year., doi:10.31235/osf.io/ey36d (2021).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.31235/osf.io/ey36d&link_type=DOI) 

60. Li, Y. & Nair, H. How reliable are COVID-19 burden estimates for India? The Lancet Infectious Diseases, doi:10.1016/S1473-3099(21)00422-9 (2021).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S1473-3099(21)00422-9&link_type=DOI) 

61. DHFW. Technical paper COVID 19. Reduction in all-cause mortality in Kerala during COVID-19 pandemic., <[https://health.kerala.gov.in/pdf/Technical-paper-All-Cause-Mortality-Kerala.pdf](https://health.kerala.gov.in/pdf/Technical-paper-All-Cause-Mortality-Kerala.pdf)> (2021).